Core Viewpoint - Zai Lab Limited (荃信生物-B) has seen a significant increase in its stock price, attributed to recent share buybacks and the announcement of a new clinical trial approval for its drug candidate QX027N [1] Group 1: Stock Performance - Zai Lab's stock rose over 7% in early trading, currently up 4.97% at HKD 21.98, with a trading volume of HKD 8.5648 million [1] - The company has been actively repurchasing shares, spending HKD 1.82407 billion to buy back a total of 901,800 shares this month [1] Group 2: Clinical Development - The company announced that its self-developed long-acting dual antibody injection QX027N has received implied approval for clinical trials from the National Medical Products Administration, aimed at treating asthma and atopic dermatitis [1] - This clinical approval marks a significant step for the company's innovative dual antibody matrix in the field of autoimmune and allergic diseases [1]
港股异动 | 荃信生物-B(02509)涨超7% 月内回购超1800万港元 QX027N获得两项临床试验默示许可